Deltex Medical Regulatory News (DEMG)

27 May 2005 10:47

Deltex Medical Group PLC27 May 2005 DELTEX MEDICAL GROUP PLC27 MAY 2005 Deltex Medical Group plc ('Deltex Medical' / 'Company') Deltex Medical Secures Another Major NHS Order for CardioQ Deltex Medical Group plc ("Deltex Medical" or "Company"), the AIM listedhaemodynamic monitoring company today announces the receipt of a further majororder from an NHS Trust to implement the Company's CardioQ(TM) system as astandard of care in moderate and major risk surgery. Worcestershire Royal Hospital, which is part of Worcestershire Acute HospitalsNHS Trust, has successfully concluded an audit using the CardioQ on patientsundergoing a range of moderate and major risk surgical procedures. The outcomeof this audit demonstrated to the satisfaction of both the Trust managers anddoctors, that a significant reduction in average length of stay across thesesurgical procedures had been achieved over the course of the exercise.Consequently, the hospital has purchased a total of 6 CardioQ monitors to beinstalled in operating theatres within Worcestershire Royal Hospital and are nowlooking to implement this technology across the rest of the Trust. Andy Hill, Deltex Medical's Chief Executive, said: "It's very pleasing to seethe results of our marketing efforts with NHS hospitals. This major order fromWorcestershire Royal Hospital and other recent placements indicate that we arestarting to see the CardioQ gather some real momentum in the marketplace. At thesame time, our discussions continue with other NHS Trusts regardingimplementation of the CardioQ and we expect to announce further orders as thesediscussions progress."For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Financial Dynamics 0207 831 3113David YatesLucy Briggs Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. Deltex Medical is developing a wholly non-invasive monitoring solution,SupraQ(TM), that will enable medical practitioners to determine a patient'shaemodynamic status and take appropriate action in any setting; at the site ofan accident, on the battlefield, in the accident and emergency department andthroughout the hospital. This device will provide vital information for doctors,allowing them to make better informed decisions, more quickly, about how best totreat their patients. The SupraQ has the potential to extend the use of DeltexMedical's proprietary monitoring technology into every environment wherepatients can benefit from early diagnosis of hypovolaemia. This information is provided by RNS The company news service from the London Stock Exchange